Abstract
Background
Objective
Design
Participants
Main outcome measure
Statistical analysis
Results
Conclusions
Keywords
Materials and Methods
Sampling Frame
Survey Description
Category | ≥ 1 AEs in Dietary Supplement Category | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Palpitations, Racing Heart | Abdominal Pain | Nausea, Vomiting | Diarrhea | Muscle Cramps, Pain, Weakness | Sleep Disturbances, Insomnia | Dizzy, Confused, Lightheaded | Tingling, Numbness | Seizures, Convulsions, Tremors | Other | ||
←% ± standard error (n)→ | |||||||||||
Combination product (n = 11,844) | 9.3 ± 0.3 (1,103) | 2.1 ± 0.1 (251) | 2.3 ± 0.1 (268) | 4.6 ± 0.2 (546) | 1.1 ± 0.1 (134) | 5.4 ± 0.2 (645) | 2.8 ± 0.2 (327) | 6.9 ± 0.2 (813) | 0.5 ± 0.1 (60) | 2.9 ± 0.2 (347) | 20.0 ± 0.4 (2,371) |
Purported prohormone (n = 1,299) | 1.4 ± 0.3 (18) | 1.3 ± 0.3 (17) | 1.2 ± 0.3 (15) | 1.0 ± 0.3 (13) | 0.7 ± 0.2 (9) | 2.1 ± 0.4 (27) | 0.8 ± 0.2 (10) | 0.8 ± 0.2 (10) | 0.3 ± 0.2 (4) | 3.2 ± 0.5 (41) | 8.0 ± 0.8 (104) |
Protein or amino acid (n = 11,146) | 1.1 ± 0.1 (122) | 0.9 ± 0.1 (104) | 0.7 ± 0.1 (74) | 2.2 ± 0.1 (245) | 0.3 ± 0.1 (39) | 0.8 ± 0.1 (90) | 0.4 ± 0.1 (45) | 0.8 ± 0.1 (89) | 0.1 ± 0.0 (11) | 1.7 ± 0.1 (195) | 6.3 ± 0.2 (707) |
Multivitamin/multimineral (n = 11,886) | 1.2 ± 0.1 (140) | 0.9 ± 0.1 (109) | 1.4 ± 0.1 (172) | 1.0 ± 0.1 (114) | 0.6 ± 0.1 (73) | 1.4 ± 0.1 (164) | 0.6 ± 0.1 (70) | 0.7 ± 0.1 (88) | 0.1 ± 0.0 (9) | 1.6 ± 0.1 (190) | 6.0 ± 0.2 (718) |
Individual vitamin or mineral (n = 8,226) | 0.8 ± 0.1 (69) | 08 ± 0.1 (78) | 0.9 ± 0.1 (78) | 1.1 ± 0.1 (87) | 0.6 ± 0.1 (50) | 0.8 ± 0.1 (62) | 0.5 ± 0.1 (44) | 0.6 ± 0.1 (52) | 0.1 ± 0.0 (12) | 2.0 ± 0.2 (166) | 5.6 ± 0.3 (463) |
Herbal substance (n = 5,332) | 0.8 ± 0.1 (45) | 0.7 ± 0.1 (39) | 0.5 ± 0.1 (28) | 1.0 ± 0.1 (55) | 0.2 ± 0.1 (10) | 0.7 ± 0.1 (37) | 0.4 ± 0.1 (21) | 0.2 ± 0.1 (13) | 0.1 ± 0.0 (3) | 1.7 ± 0.2 (89) | 4.3 ± 0.3 (231) |
Joint health product (n = 2,514) | 0.1 ± 0.1 (2) | 0.3 ± 0.1 (8) | 0.2 ± 0.1 (4) | 0.5 ± 0.1 (12) | 0.3 ± 0.1 (7) | 0.2 ± 0.1 (5) | 0.0 ± 0.0 (1) | 0.1 ± 0.1 (3) | 0.0 ± 0.0 (0) | 1.0 ± 0.2 (25) | 2.0 ± 0.3 (51) |
Other (n = 8,177) | 0.2 ± 0.1 (17) | 0.3 ± 0.1 (26) | 0.3 ± 0.1 (28) | 0.4 ± 0.1 (35) | 0.1 ± 0.0 (9) | 1.1 ± 0.1 (88) | 0.5 ± 0.1 (38) | 0.2 ± 0.0 (15) | 0.0 ± 0.0 (1) | 1.4 ± 0.1 (118) | 3.7 ± 0.2 (299) |
Combined AEs (n = 19,731) | 6.7 ± 0.7 (1,325) | 2.6 ± 0.7 (511) | 2.9 ± 0.7 (574) | 4.7 ± 0.7 (920) | 1.4 ± 0.7 (276) | 4.6 ± 0.7 (917) | 2.5 ± 0.7 (492) | 4.9 ± 0.7 (975) | 0.4 ± 0.7 (84) | 4.5 ± 0.7 (897) |
Data Analysis
IBM SPSS Statistics for Windows. Version 27.0. IBM Corportation; 2020. Accessed February 7. https://www.ibm.com/products/spss-statistics

Results
Prevalence of Self-Reported AEs
Adverse effect | 1-2 Dietary Supplements (n = 5,303) | 3-4 Dietary Supplements (n = 3,741) | ≥ 5 Dietary Supplements (n = 10,687) | Risk ratio (95% CI) | P value | P value |
---|---|---|---|---|---|---|
←% ± standard error (n)→ | ||||||
Palpitations, racing heart | 3.1 ± 0.2 (166) | 5.0 ± 0.4 (187) | 9.1 ± 0.3 (972) | 2.91 (2.47-3.41) | < 0.01 | < 0.01 |
Abdominal pain | 1.1 ± 0.1 (59) | 2.1 ± 0.2 (80) | 3.5 ± 0.2 (372) | 2.48 (1.96-3.13) | < 0.01 | < 0.01 |
Nausea, vomiting | 1.5 ± 0.2 (82) | 2.2 ± 0.2 (83) | 3.8 ± 0.2 (409) | 2.48 (1.96-3.13) | < 0.01 | < 0.01 |
Diarrhea | 2.0 ± 0.2 (104) | 3.6 ± 0.3 (133) | 6.4 ± 0.2 (683) | 3.26 (2.66-4.00) | < 0.01 | < 0.01 |
Muscle cramps, pain, weakness | 0.5 ± 0.1 (29) | 1.0 ± 0.2 (39) | 1.9 ± 0.1 (208) | 3.56 (2.42-5.24) | < 0.01 | < 0.01 |
Sleep disturbances, insomnia | 2.1 ± 0.2 (113) | 3.4 ± 0.3 (129) | 6.3 ± 0.2 (675) | 2.96 (2.44-3.61) | < 0.01 | < 0.01 |
Dizzy, confused, lightheaded | 1.2 ± 0.1 (65) | 1.7 ± 0.2 (62) | 3.4 ± 0.2 (365) | 2.79 (2.15-3.62) | < 0.01 | < 0.01 |
Tingling, numbness | 1.8 ± 0.2 (98) | 3.3 ± 0.3 (124) | 7.0 ± 0.2 (753) | 3.81 (3.10-4.69) | < 0.01 | < 0.01 |
Seizures, convulsions, tremors | 0.0 ± 0.0 (2) | 0.3 ± 0.1 (10) | 0.7 ± 0.1 (72) | 17.86 (4.39-72.77) | < 0.01 | < 0.01 |
Other | 2.5 ± 0.2 (132) | 4.1 ± 0.3 (152) | 5.7 ± 0.2 (613) | 2.30 (1.92-2.77) | < 0.01 | < 0.01 |
Individuals reporting ≥ 1 adverse effects | 10.3 ± 0.4 (546) | 16.0 ± 0.6 (600) | 23.3 ± 0.4 (2,486) | 2.26 (2.07-2.46) | <0.01 | <0.01 |
Factors Associated with AEs (Univariable Analyses)
Variable | Strata | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Any DS Users | Combination Product Users | Purported Pro-hormone Users | Protein/Amino Acid Users | MVM Users | Individual Vitamin/Mineral Users | Herbal Users | Joint Health Product Users | Other DS Users | ||
←% ± standard error→ | ||||||||||
Gender | Male | 17.9 ± 0.3 | 19.4 ± 0.4 | 8.0 ± 0.8 | 5.9 ± 0.2 | 5.6 ± 0.2 | 4.9 ± 0.3 | 4.2 ± 0.3 | 1.9 ± 0.3 | 3.6 ± 0.2 |
Female | 21.3 ± 0.8 | 24.3 ± 1.1 | 10.0 ± 3.1 | 9.1 ± 0.8 | 8.3 ± 0.6 | 8.7 ± 0.7 | 4.6 ± 0.6 | 2.5 ± 0.8 | 3.9 ± 0.6 | |
P value | < 0.01 | < 0.01 | 0.68 | < 0.01 | < 0.01 | < 0.01 | 0.57 | 0.49 | 0.58 | |
Age (y) | 18-24 | 20.8 ± 0.7 | 21.7 ± 0.9 | 9.6 ± 2.2 | 7.0 ± 0.6 | 6.3 ± 0.6 | 5.1 ± 0.6 | 3.5 ± 0.7 | 2.3 ± 1.1 | 4.7 ± 0.6 |
25-29 | 18.6 ± 0.6 | 19.5 ± 0.8 | 6.9 ± 1.7 | 5.8 ± 0.4 | 5.9 ± 0.5 | 5.1 ± 0.5 | 3.8 ± 0.6 | 1.4 ± 0.6 | 2.6 ± 0.4 | |
30-39 | 18.3 ± 0.4 | 20.1 ± 0.6 | 8.1 ± 1.1 | 6.4 ± 0.4 | 5.5 ± 0.3 | 5.8 ± 0.4 | 4.5 ± 0.4 | 1.6 ± 0.4 | 3.3 ± 0.3 | |
≥ 40 | 16.7 ± 0.6 | 18.8 ± 0.9 | 8.0 ± 1.5 | 5.6 ± 0.6 | 7.2 ± 0.5 | 6.1 ± 0.6 | 5.0 ± 0.6 | 3.2 ± 0.7 | 4.7 ± 0.5 | |
P value, | < 0.01/< 0.01 | 0.13/0.06 | 0.80/0.75 | 0.22/0.21 | 0.04/0.35 | 0.51/0.15 | 0.32/0.06 | 0.07/0.11 | < 0.01/0.48 | |
Education | Some HS/HS graduate | 19.7 ± 0.8 | 20.1 ± 1.0 | 8.8 ± 2.0 | 7.1 ± 0.6 | 6.9 ± 0.7 | 6.5 ± 0.8 | 4.5 ± 0.9 | 2.7 ± 1.2 | 4.0 ± 0.6 |
Some college | 20.3 ± 0.4 | 21.0 ± 0.5 | 7.7 ± 1.1 | 6.9 ± 0.4 | 6.8 ± 0.4 | 5.7 ± 0.4 | 3.9 ± 0.4 | 2.0 ± 0.4 | 3.7 ± 0.3 | |
College degree | 16.1 ± 0.4 | 18.9 ± 0.6 | 8.0 ± 1.2 | 5.2 ± 0.3 | 5.2 ± 0.3 | 5.3 ± 0.4 | 4,6 ± 0.4 | 1.9 ± 0.4 | 3.4 ± 0.3 | |
P value, | < 0.01/< 0.01 | 0.03/0.07 | 0.89/0.82 | < 0.01/< 0.01 | < 0.01/< 0.01 | 0.41/0.19 | 0.48/0.52 | 0.80/0.58 | 0.63/0.34 | |
Body mass index | < 25.0 | 16.5 ± 0.5 | 18.6 ± 0.7 | 11.1 ± 2.2 | 6.5 ± 0.5 | 5.2 ± 0.4 | 5.7 ± 0.5 | 3.5 ± 0.5 | 1.9 ± 0.6 | 4.3 ± 0.4 |
25.0-29.9 | 18.7 ± 0.4 | 20.2 ± 0.5 | 6.3 ± 0.9 | 6.2 ± 0.3 | 6.1 ± 0.3 | 5.2 ± 0.3 | 4.3 ± 0.4 | 2.2 ± 0.4 | 3.5 ± 0.3 | |
≥ 30.0 | 20.7 ± 0.7 | 21.5 ± 0.9 | 8.9 ± 1.5 | 6.5 ± 0.6 | 6.9+0.5 | 6.8 ± 0.6 | 5.3 ± 0.7 | 1.0 ± 0.4 | 3.2 ± 0.5 | |
P value, | < 0.01/< 0.01 | 0.04/0.01 | 0.05/0.61 | 0.83/0.93 | 0.04/0.01 | 0.07/0.23 | 0.09/0.03 | 0.25/0.30 | 0.20/0.09 | |
Aerobic exercise duration (min/wk) | ≤ 90 | 19.0 ± 0.5 | 21.2 ± 0.7 | 7.0 ± 1.5 | 6.9 ± 0.5 | 5.5 ± 0.4 | 5.8 ± 0.5 | 5.2 ± 0.6 | 2.4 ± 0.6 | 4.3 ± 0.4 |
91-180 | 17.6 ± 0.5 | 21.1 ± 0.8 | 9.3 ± 1.7 | 5.9 ± 0.5 | 5.5 ± 0.4 | 5.1 ± 0.5 | 3.6 ± 0.5 | 1.1 ± 0.4 | 3.3 ± 0.4 | |
181-300 | 18.1 ± 0.6 | 19.1 ± 0.8 | 8.5 ± 1.6 | 5.6 ± 0.5 | 6.2 ± 0.5 | 5.6 ± 0.5 | 4.1 ± 0.6 | 2.8 ± 0.7 | 3.4 ± 0.4 | |
> 300 | 18.8 ± 0.6 | 18.8 ± 0.7 | 7.6 ± 1.3 | 6.6 ± 0.4 | 7.0 ± 0.5 | 5.9 ± 0.5 | 4.3 ± 0.5 | 1.9 ± 0.5 | 3.5 ± 0.4 | |
P value, | 0.23/0.98 | 0.02/<0.01 | 0.75/0.94 | 0.17/0.57 | 0.07/0.01 | 0.65/0.70 | 0.23/0.42 | 0.20/0.98 | 0.32/0.24 | |
Resistance training duration (min/wk) | ≤ 45 | 17.1 ± 0.5 | 21.9 ± 0.9 | 7.2 ± 2.1 | 7.3 ± 0.7 | 7.6 ± 0.5 | 6.4 ± 0.5 | 5.1 ± 0.6 | 2.0 ± 0.7 | 5.4 ± 0.6 |
46-135 | 16.4 ± 0.6 | 20.6 ± 0.9 | 9.8 ± 2.3 | 5.3 ± 0.5 | 5.3 ± 0.4 | 5.3 ± 0.5 | 3.9 ± 0.6 | 1.8 ± 0.6 | 3.5 ± 0.5 | |
136-300 | 19.1 ± 0.5 | 19.6 ± 0.7 | 8.0 ± 1.5 | 6.3 ± 0.4 | 5.4 ± 0.4 | 5.7 ± 0.5 | 3.8 ± 0.5 | 2.4 ± 0.6 | 3.2 ± 0.4 | |
> 300 | 20.6 ± 0.6 | 19.2 ± 0.6 | 7.7 ± 1.1 | 6.3 ± 0.4 | 5.8 ± 0.4 | 5.1 ± 0.5 | 4.4 ± 0.5 | 1.8 ± 0.5 | 3.0 ± 0.3 | |
P value, | < 0.01/< 0.01 | 0.07/< 0.01 | 0.80/0.78 | 0.11/0.80 | < 0.01/0.01 | 0.26/0.10 | 0.33/0.43 | 0.84/0.99 | < 0.01/< 0.01 | |
Smoking | Never smoked | 17.0 ± 0.3 | 18.8 ± 0.5 | 8.9 ± 1.1 | 6.0 ± 0.3 | 5.8 ± 0.3 | 5.6 ± 0.3 | 4.3 ± 0.3 | 2.2 ± 0.4 | 3.7 ± 0.3 |
Smoked but quit | 19.7 ± 0.7 | 20.9 ± 0.8 | 6.9 ± 1.5 | 6.3 ± 0.5 | 6.2 ± 0.5 | 5.2 ± 0.6 | 5.5 ± 0.7 | 1.8 ± 0.6 | 3.6 ± 0.5 | |
Smoker | 21.7 ± 0.7 | 23.0 ± 0.9 | 7.4 ± 1.6 | 6.9 ± 0.6 | 6.8 ± 0.6 | 5.9 ± 0.7 | 2.9 ± 0.6 | 1.6 ± 0.6 | 3.6 ± 0.5 | |
P value | < 0.01 | < 0.01 | 0.52 | 0.29 | 0.21 | 0.70 | 0.02 | 0.70 | 0.96 | |
Smokeless tobacco use | Never used | 17.8 ± 0.3 | 19.8 ± 0.4 | 8.4 ± 0.9 | 6.1 ± 0.3 | 5.8 ± 0.2 | 5.7 ± 0.3 | 4.4 ± 0.3 | 2.0 ± 0.3 | 3.6 ± 0.2 |
Used but quit | 19.5 ± 1.0 | 20.3 ± 1.2 | 5.3 ± 1.9 | 6.9 ± 0.8 | 5.4 ± 0.7 | 4.1 ± 0.8 | 3.4 ± 0.9 | 0.9 ± 0.6 | 3.9 ± 0.7 | |
User | 21.2 ± 0.8 | 21.3 ± 1.0 | 8.8 ± 1.8 | 6.5 ± 0.6 | 7.1 ± 0.7 | 5.9 ± 0.8 | 4.6 ± 0.8 | 3.0 ± 0.9 | 3.7 ± 0.6 | |
P value | < 0.01 | 0.33 | 0.42 | 0.47 | 0.13 | 0.23 | 0.60 | 0.21 | 0.95 | |
Alcohol intake (mL/wk) | 0 | 16.6 ± 0.5 | 17.6 ± 0.7 | 7.3 ± 1.4 | 6.3 ± 0.4 | 5.7 ± 0.4 | 5.9 ± 0.5 | 4.5 ± 0.5 | 1.5 ± 0.5 | 3.7 ± 0.4 |
0.23-24.85 | 17.9 ± 0.6 | 19.1 ± 0.8 | 9.1 ± 1.8 | 6.0 ± 0.5 | 6.0 ± 0.5 | 5.9 ± 0.5 | 3.6 ± 0.5 | 1.8 ± 0.5 | 3.5 ± 0.4 | |
24.86-71.69 | 18.2 ± 0.6 | 19.6 ± 0.7 | 6.8 ± 1.4 | 6.0 ± 0.4 | 5.6 ± 0.4 | 5.2 ± 0.5 | 3.9 ± 0.5 | 2.5 ± 0.6 | 3.3 ± 0.4 | |
≥ 71.70 | 21.4 ± 0.6 | 24.0 ± 0.8 | 9.0 ± 1.5 | 6.7 ± 0.5 | 7.0 ± 0.5 | 5.3 ± 0.5 | 5.1 ± 0.6 | 2.3 ± 0.6 | 4.0 ± 0.4 | |
P value, | < 0.01/< 0.01 | < 0.01/< 0.01 | 0.62/0.60 | 0.66/0.53 | 0.08/0.06 | 0.61/0.25 | 0.26/0.44 | 0.54/0.21 | 0.66/0.68 | |
Service | Air Force | 14.7 ± 0.4 | 16.8 ± 0.6 | 8.0 ± 1.5 | 5.4 ± 0.4 | 4.6 ± 0.3 | 4.0 ± 0.4 | 3.1 ± 0.4 | 1.7 ± 0.4 | 2.8 ± 0.3 |
Army | 19.8 ± 0.5 | 20.3 ± 0.7 | 6.5 ± 1.1 | 6.2 ± 0.4 | 6.2 ± 0.4 | 6.4 ± 0.5 | 5.2 ± 0.5 | 2.2 ± 0.5 | 3.9 ± 0.4 | |
Marine Corps | 22.3 ± 0.9 | 23.0 ± 1.0 | 9.1 ± 2.0 | 6.8 ± 0.6 | 7.7 ± 0.7 | 5.8 ± 0.8 | 3.9 ± 0.8 | 2.9 ± 1.0 | 3.9 ± 0.6 | |
Navy | 20.5 ± 0.6 | 23.0 ± 0.9 | 10.3 ± 1.9 | 7.5 ± 0.6 | 7.6 ± 0.5 | 7.2 ± 0.6 | 4.9 ± 0.6 | 1.9 ± 0.6 | 4.5 ± 0.5 | |
P value | < 0.01 | < 0.01 | 0.28 | 0.01 | < 0.01 | < 0.01 | 0.01 | 0.63 | 0.03 |
Factors Independently Associated with AEs (Multivariable Analyses)
Variable | Strata | Any DS Users (n = 18,522) | Combination Product Users (n = 11,120) | Purported Prohormone Users (n = 1,221) | Protein/Amino Acid Users (n = 10,630) | Multivitamin/Multimineral Users (n = 11,165) | Individual Vitamin/Mineral Users (n = 7,704) | Herbal Users (n = 5,057) | Joint Health Product Users (n = 2,375) | Other DS Users (n = 7,707) |
---|---|---|---|---|---|---|---|---|---|---|
←Odds ratio (95% CI)→ | ||||||||||
Gender | Male | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Female | 1.49 (1.34-1.67) | 1.48 (1.29-1.72) | 0.98 (0.27-3.50) | 1.73 (1.37-2.20) | 1.79 (1.46-2.22) | 2.09 (1.65-2.65) | 1.25 (0.88-1.79) | 2.23 (1.00-5.01) | 1.07 (0.75-1.52) | |
Age (y) | 18-24 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
25-29 | 0.81 (0.71-0.92) | 0.80 (0.69-0.93) | 0.76 (0.35-1.68) | 0.84 (0.65-1.09) | 0.97 (0.73-1.29) | 1.04 (0.71-1.51) | 1.00 (0.59-1.72) | 0.43 (0.09-1.71) | 0.54 (0.35-0.83) | |
30-39 | 0.82 (0.72-0.92) | 0.81 (0.70-0.94) | 0.99 (0.48-2.03) | 1.01 (0.79-1.28) | 0.90 (0.67-1.19) | 1.32 (0.93-1.87) | 1.18 (0.71-1.97) | 0.76 (0.22-2.58) | 0.71 (0.48-1.04) | |
≥ 40 | 0.76 (0.65-0.88) | 0.74 (0.61-0.89) | 0.86 (0.37-1.98) | 0.90 (0.65-1.23) | 1.18 (0.87-1.62) | 1.37 (0.92-2.05) | 1.19 (0.67-2.10) | 2.02 (0.55-7.49) | 0.93 (0.60-1.44) | |
Education | HS/HS graduate | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Some college | 1.12 (0.99-1.28) | 1.17 (1.00-1.36) | 0.92 (0.47-1.79) | 1.00 (0.78-1.28) | 0.96 (0.73-1.26) | 0.79 (0.56-1.11) | 0.78 (0.47-1.27) | 0.95 (0.29-3.13) | 1.10 (0.72-1.66) | |
College degree | 0.90 (0.78-1.03) | 1.04 (0.88-1.23) | 0.92 (0.44-1.92) | 0.71 (0.76-1.26) | 0.67 (0.49-0.90) | 0.67 (0.46-0.95) | 0.90 (0.54-1.51) | 0.52 (0.15-1.85) | 0.88 (0.56-1.39) | |
Body mass index | < 25.0 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
25.0-29.9 | 1.16 (1.05-1.27) | 1.16 (1.03-1.31) | 0.50 (0.29-0.88) | 0.98 (0.81-1.18) | 1.25 (1.03-1.53) | 1.02 (0.80-1.29) | 1.24 (0.88-1.75) | 1.16 (0.55-2.44) | 0.83 (0.63-1.10) | |
≥ 30.0 | 1.28 (1.13-1.44) | 1.26 (1.08-1.45) | 0.72 (0.39-1.33) | 0.98 (0.76-1.25) | 1.37 (1.07-1.75) | 1.33 (1.00-1.67) | 1.48 (0.98-2.24) | 0.39 (0.12-1.28) | 0.75 (0.52-1.10) | |
Aerobic exercise duration (min/wk) | ≤ 90 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
91-180 | 0.95 (0.85-1.06) | 0.98 (0.86-1.11) | 1.26 (0.66-2.40) | 0.87 (0.69-1.09) | 1.08 (0.86-1.37) | 0.88 (0.66-1.17) | 0.67 (0.45-1.00) | 0.46 (0.18-1.20) | 0.76 (0.54-1.06) | |
181-300 | 0.94 (0.84-1.05) | 0.87 (0.76-1.00) | 1.22 (0.64-2.33) | 0.79 (0.62-1.00) | 1.30 (1.02-1.65) | 0.97 (0.72-1.30) | 0.75 (0.51-1.12) | 0.84 (0.37-1.89) | 0.81 (0.57-1.15) | |
> 300 | 0.91 (0.81-1.01) | 0.87 (0.76-0.99) | 1.12 (0.60-2.10) | 0.96 (0.77-1.20) | 1.55 (1.23-1.96) | 1.07 (0.80-1.42) | 0.80 (0.54-1.18) | 0.75 (0.32-1.77) | 0.93 (0.66-1.31) | |
Resistance training duration (min/wk) | ≤ 45 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
46-135 | 0.92 (0.82-1.04) | 0.91 (0.77-1.06) | 1.15 (0.49-2.71) | 0.74 (0.55-1.00) | 0.69 (0.54-0.87) | 0.88 (0.66-1.19) | 0.83 (0.55-1.23) | 1.12 (0.40-3.10) | 0.64 (0.45-0.91) | |
136-300 | 0.94 (0.84-1.05) | 0.84 (0.72-0.97) | 0.85 (0.39-1.87) | 0.88 (0.68-1.15) | 0.61 (0.48-0.77) | 0.96 (0.72-1.29) | 0.81 (0.54-1.21) | 1.52 (0.60-3.84) | 0.59 (0.41-0.84) | |
> 300 | 0.92 (0.81-1.04) | 0.79 (0.68-0.92) | 0.82 (0.38-1.78) | 0.78 (0.60-1.03) | 0.56 (0.43-0.72) | 0.86 (0.63-1.18) | 0.89 (0.58-1.36) | 1.26 (0.45-3.55) | 0.55 (0.38-0.80) | |
Smoking | Never smoked | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Smoked but quit | 1.12 (1.00-1.24) | 1.12 (0.98-1.27) | 0.82 (0.44-1.50) | 0.95 (0.76-1.18) | 1.03 (0.83-1.28) | 0.96 (0.72-1.27) | 1.30 (0.91-1.86) | 0.79 (0.34-1.79) | 0.97 (0.70-1.35) | |
Smoker | 1.23 (1.11-1.37) | 1.23 (1.09-1.40) | 0.75 (0.42-1.33) | 1.10 (0.89-1.36) | 1.13 (0.90-1.41) | 1.08 (0.81-1.44) | 0.63 (0.40-0.99) | 0.62 (0.24-1.60) | 0.93 (0.66-1.33) | |
Smokeless tobacco use | Never used | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Used but quit | 1.00 (0.87-1.15) | 0.96 (0.81-1.14) | 0.54 (0.22-1.33) | 1.18 (0.90-1.57) | 0.87 (0.63-1.19) | 0.83 (0.54-1.28) | 0.59 (0.32-1.08) | 0.53 (0.12-2.41) | 1.09 (0.71-1.69) | |
User | 1.01 (0.90-1.13) | 0.97 (0.84-1.11) | 1.15 (0.67-1.98) | 1.02 (0.81-1.29) | 1.13 (0.88-1.44) | 1.10 (0.80-1.52) | 1.07 (0.69-1.67) | 2.14 (0.95-4.81) | 1.05 (0.72-1.52) | |
Alcohol intake (mL/wk) | 0 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
0.23-24.85 | 1.16 (1.04-1.29) | 1.10 (0.96-1.27) | 1.24 (0.66-2.34) | 0.98 (0.77-1.23) | 1.14 (0.91-1.43) | 1.01 (0.78-1.32) | 0.83 (0.55-1.23) | 1.68 (0.64-4.43) | 0.97 (0.69-1.36) | |
24.86-71.69 | 1.16 (1.04-1.30) | 1.14 (1.00-1.31) | 1.05 (0.56-1.97) | 1.06 (0.84-1.32) | 1.13 (0.90-1.43) | 0.97 (0.74-1.28) | 0.95 (0.64-1.41) | 2.20 (0.90-5.88) | 0.94 (0.67-1.32) | |
≥ 71.70 | 1.38 (1.23-1.53) | 1.43 (1.25-1.63) | 1.27 (0.71-2.26) | 1.14 (0.91-1.43) | 1.42 (1.13-1.78) | 0.97 (0.72-1.29) | 1.27 (0.87-1.85) | 1.88 (0.70-5.06) | 1.08 (0.77-1.51) | |
Service branch | Air Force | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Army | 1.47 (1.33-1.62) | 1.35 (1.19-1.53) | 0.89 (0.49-1.60) | 1.24 (1.01-1.53) | 1.27 (1.03-1.57) | 1.70 (1.31-2.21) | 1.61 (1.12-2.32) | 1.49 (0.67-3.30) | 1.56 (1.13-2.16) | |
Marine Corps | 1.57 (1.38-1.78) | 1.59 (1.36-1.85) | 1.40 (0.70-2.79) | 1.25 (0.96-1.61) | 1.65 (1.25-2.17) | 1.76 (1.21-2.54) | 1.25 (0.73-2.12) | 2.02 (0.76-5.37) | 1.54 (1.01-2.33) | |
Navy | 1.49 (1.34-1.65) | 1.44 (1.26-1.64) | 1.45 (0.78-2.70) | 1.42 (1.13-1.77) | 1.54 (1.24-1.90) | 1.80 (1.37-2.36) | 1.43 (0.98-2.09) | 1.22 (0.49-3.26) | 1.59 (1.14-2.22) | |
No. of DS Consumed | 1-2 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
2-4 | 1.64 (1.44-1.86) | 1.21 (1.01-1.45) | 1.40 (0.70-4.61) | 1.73 (1.16-2.59) | 1.11 (0.82-1.52) | 0.77 (0.52-1.14) | 0.75 (0.43-1.29) | 0.70 (0.15-3.26) | 0.64 (0.41-1.00) | |
≥ 5 | 2.59 (2.32-2.88) | 1.33 (1.14-1.55) | 1.45 (0.78-2.70) | 2.09 (1.46-2.99) | 1.67 (1.29-2.15) | 0.86 (0.62-1.18) | 0.76 (0.49-1.17) | 0.71 (0.21-2.44) | 0.71 (0.42-1.00) |
Discussion
Prevalence of AEs
Factors Associated with AEs in DS Categories
- Army U.S.
Physical fitness and body fat program.
Strengths and Limitations
Conclusions
Acknowledgements
Author Contributions
References
- Dietary Supplement Health and Education Act of 1994. Pub L 103-417, 103rd Congress.https://ods.od.nih.gov/About/dshea_Wording.aspxDate accessed: July 14, 2015
- Why the United States still needs improved dietary supplement regulation and oversight.Clin Pharmacol Ther. 2008; 83: 391-393
- Dietary supplement adverse event reporting data for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004-2013.Ann Pharmacother. 2018; 52: 431-438
- FDA issues regulation prohibiting sale of dietary supplements containing ephedrine alkaloids and reiterates its advice that consumers stop using these products.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108242.htmDate accessed: December 2, 2015
- FDA warns consumers to stop using Hydroxycut products. Dietary supplement linked to one death; pose risk of liver injury.https://www.quackwatch.org/02ConsumerProtection/FDAActions/hydroxycut.htmlDate accessed: May 22, 2020
- DMAA in dietary supplements.https://wayback.archive-it.org/7993/20170722025648/https://www.fda.gov/Food/DietarySupplements/ProductsIngredients/ucm346576.htmDate accessed: November 24, 2020
- Hemorrhagic stroke in a young healthy male following use of a pre-workout supplement Animal Rage XL.Milit Med. 2017; 182: e2030-e2033
- A case report of supplement-induced hepatitis in an active duty service member.Milit Med. 2015; 180: e844-e846
- Suspected dietary supplement injuries in Special Operations soldiers.J Spec Oper Med. 2010; 10: 14-24
- Case reports: death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamyamine.Milit Med. 2012; 177: 1455-1459
- Glutamine powder-induced hepatotoxicity: it is time to understand the side effects of sports nutritional supplements.Gastroenterol Hepatol Bed Bench. 2020; 13: 86-89
- Toxic hepatitis in a group of 20 male body builders taking dietary supplements.Food Chem Toxicol. 2012; 50: 3826-3832
- Cytotoxic lesions of the corpus callosum caused by thermogenic dietary supplements.Am J Neuroradiol. 2019; 40: 1304-1308
- Pre-workout supplement induced cardiac ischaemia in a young female.J Sports Sci. 2020; 39: 187-191
- Behavior of consumers, physicians and pharmacists in response to adverse events associated with dietary supplement use.Nutr J. 2017; 16: 18
- Prevalence of medication-dietary supplement combined use and associated factors.Nutrients. 2019; 11: 2466
- Dietary supplements: regulatory challenges and research resources.Nutrients. 2018; 10: 41
- An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series.Food Chem Toxicol. 2017; 107: 449-471
- Self-reported side-effects associated with the use of dietary supplements in an Armed Forces population.Drug Test Anal. 2016; 8: 287-295
- Prevalence, adverse effects, and factors associated with dietary supplement and nutritional supplement use by United States Navy and Marine Corps personnel.J Acad Nutr Diet. 2016; 116: 1423-1442
- Prevalence and factors associated with dietary supplement use in a stratified random sample of United States military personnel: the US Military Dietary Supplement Use Study.J Nutr. 2021; 151: 3495-3506
- Meta-analysis of randomized trials of monetary incentives and response to mailed questionnaires.J Epidemiol Community Health. 2005; 59: 987-999
- Estimating the effect of incentives on mail survey response rates: a meta-analysis.Public Opin Q. 1993; 57: 62-79
- Use of dietary supplements among active-duty US Army soldiers.Am J Clin Nutr. 2010; 92: 985-995
- Predictors of dietary supplement use by US Coast Guard personnel.PLOS One. 2015; 10e133006
- Demographic, lifestyle factors and reasons for use of dietary supplements by Air Force personnel.Aerosp Med Human Perform. 2016; 87: 628-637
IBM SPSS Statistics for Windows. Version 27.0. IBM Corportation; 2020. Accessed February 7. https://www.ibm.com/products/spss-statistics
- What is a standard drink?.https://www.niaaa.nih.gov/what-standard-drinkDate accessed: May 21, 2020
- Nutritional and sports supplements used among deployed U.S. Army soldiers in a remote, austere combat outpost in Eastern Afghanistan.Milit Med. 2015; 180: 391-401
- Dietary supplement intake in the active duty enlisted population.US Army Med Dep J. 2004; Oct-Dec: 44-56
- Findings of recent surveys on dietary supplements use by military personnel and the general population (Appendix C).in: Use of Dietary Supplements by Military Personnel. National Academy Press, 2008: 384-385
- Patterns and perceptions of supplement use by U.S. Marines deployed to Afghanistan.Milit Med. 2013; 178: 659-664
- Self-administration of exercise and dietary supplements in deployed British military personnel during operation TELIC 13.J R Army Med Corps. 2010; 156: 32-36
- Self-reported dietary supplement use in deployed United States service members pre-deploymen vs. post-deployment, Afghanistan, 2013-2014.Milit Med Res. 2017; 4: 34
- Dietary supplements in a national survey: prevalence of use and reports of adverse events.J Am Dietet Assoc. 2006; 106: 1966-1974
- Prevalence of, and factors associated with health supplement use in Dubai, United Arab Emirates: a population-based cross-sectional study.BMC Complement Altern Med. 2019; 19: 172
- Concomitate use of dietary supplements and medicines in patients due to miscommunication with physicians in Japan.Nutrients. 2015; 7: 2947-2960
- Why US adults use dietary supplements.JAMA Intern Med. 2013; 173: 355-361
- Use of vitamin, mineral nonvitamin and nonmineral supplements in the United States: the 1987, 1992 and 2000 National Health Interview Survey results.J Am Diet Assoc. 2004; 104: 942-950
- Multi-ingredient pre-workout supplements, safety implications, and performance outcomes: a brief review.J Int Soc Sports Nutr. 2018; 15: 41
- Concomitant dietary supplement and prescription medication use is prevalent among US adults with doctor-informed medical conditions.J Acad Nutr Diet. 2014; 114: 1784-1790
- Liver injury from herbal and dietary supplements.Hepatology. 2017; 65: 363-373
- Somatic symptoms in the German general population from 1975-to 2013.Sci Rep. 2020; 10: 1595
- Symptoms reporting in a general population in Norway: results from the Ullensaker study.Scand J Prim Health Care. 2013; 31: 36-42
- Age and sex related self-reported symptoms in a general population across 30 years: patterns of reporting and secular trends.PLOS One. 2019; 14e0211532
- Somatic symptom reporting in women and men.J Gen Intern Med. 2001; 16: 266-275
- Qualitative sex differences in pain processing: emerging evidence of a biased literature.Nat Rev Neurosci. 2020; 21: 353-365
- Gender differences in the response to noxious stimuli.Pain Forum. 1995; 4: 209-221
- Gender and symptom sensitivity: report on a Philippine study.Am J Orthopsychiat. 1985; 55: 446-450
- Gender differences in the utilization of health care services.J Family Pract. 2000; 49: 147-152
- Fitness Program (Air Force Instruction 36-2905) (Change 1, 27 August 2015).
- Marine Corps Body Composition and Military Appearance Program, Marine Corps Order 6110.3.
- US Navy: Physical Readiness Program, OPNAV Instruction 6110.1J. Department of the Navy, Washington DC2011
- The Army Body Composition Program, Army Regulation 600-9.https://www.armyresilience.army.mil/ard/images/pdf/Policy/AR%20600-9%20The%20Army%20Body%20Composition%20Program.pdfDate accessed: February 7, 2022
- Dietary supplement use in a large, representative sample of the United States Armed Forces.J Acad Nutr Diet. 2018; 118: 1370-1388
- Physical fitness and body fat program.https://www.esd.whs.mil/Portals/54/Documents/DD/issuances/dodd/130801p.pdfDate accessed: July 20, 2021
- Drug interactions involving ethanol and alcoholic beverages.Expert Opin Drug Metab Toxicol. 2007; 5: 719-731
- An appraisal of potential drug interactions in smokers and alcohol drinkers.J Am Podiatr Med Assoc. 2009; 99: 81-88
- Epidemiological evidence and possible mechanisms for the association between cigarette smoking and injuries (Part 1).J Spec Oper Med. 2018; 18: 108-112
- Tobacco smoke in the workplace: an occupational health hazard.Can Med Assoc J. 1984; 131: 1199-1204
- Nepinephrine and epinephrine release adrenergtic mediation of smoking-associated hemodynamic and metabolic events.New Engl J Med. 1976; 295: 573-577
- Clinical pharmacology of nicotine.Ann Rev Med. 1986; 37: 21-32
- A survey instrument to assess intake of dietary supplements, related products, and caffeine in high-use populations.J Nutr. 2018; 148: 1445S-1451S
- Common method biases in behavioral research: a critical review of the literature and recommended remedies.J Appl Psychol. 2003; 88: 879-903
- Response bias, social desirability and dissimulation.Pers Individ Diff. 1985; 7: 385-400
- Nocebo phenomena in medicine.Dtsch Arzlebl Int. 2012; 109: 459-465
- Surveillance of the Armed Forces as a sentinel system for detecting adverse effects of dietary supplements in the general population.Public Health Nutr. 2017; 21: 882-887
Biography
Article info
Publication history
Footnotes
STATEMENT OF POTENTIAL CONFLICT OF INTEREST No potential conflict of interest was reported by the authors.
FUNDING/SUPPORT This work was supported by the Department of Defense Center Alliance for Nutrition and Dietary Supplement Research of the Defense Medical Research and Development Program, the US Army Medical Research and Development Command.
We are employees of the U.S. Government. This work was prepared as part of our official duties. Title 17, U.S.C. §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C. §101 defines a U.S. Government work as work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties. This work was supported by the Department of Defense Center Alliance for Nutrition and Dietary Supplement Research of the Defense Medical Research and Development Program, the U.S. Army Medical Research and Development Command (USAMRDC) under work unit no. N1335. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. The study protocol was approved by the Naval Health Research Center Institutional Review Board in compliance with all applicable Federal regulations governing the protection of human subjects. Research data were derived from an approved Naval Health Research Center, Institutional Review Board protocol number NHRC.2016.0025.The opinions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense. Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations. Approved for public release; distribution is unlimited.
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy